Drugs that contain Oxymetazoline Hydrochloride

1. Drug name - RHOFADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists Jan, 2024

(1 year, 3 months from now)

US8420688 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists Aug, 2024

(1 year, 9 months from now)

US7812049 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists May, 2028

(5 years from now)

US8883838 EPI HLTH Pharmaceutical cream compositions and methods of use Dec, 2031

(9 years from now)

US9974773 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

US10335391 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

US10751325 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment; Once daily topical treatment of persistent facial erythema associated with rosacea in adults

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

2. Drug name - UPNEEQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9867808 RVL PHARMS Compositions and methods for non-surgical treatment of Ptosis Aug, 2031

(8 years from now)

US8357714 RVL PHARMS Compositions and methods for non-surgical treatment of ptosis Aug, 2031

(8 years from now)

US10912765 RVL PHARMS Compositions and methods for non-surgical treatment of ptosis Aug, 2031

(8 years from now)

US10799481 RVL PHARMS Compositions and methods for treating ocular disorders Dec, 2039

(17 years from now)

US11103482 RVL PHARMS Oxymetazoline compositions Dec, 2039

(17 years from now)

US10940138 RVL PHARMS Compositions and methods for treating ocular disorders Dec, 2039

(17 years from now)

US10898573 RVL PHARMS Oxymetazoline compositions Dec, 2039

(17 years from now)

US10814001 RVL PHARMS Oxymetazoline compositions Dec, 2039

(17 years from now)

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.